KIF20A and non-small cell lung carcinoma: Kaplan-Meier survival analysis demonstrated significantly reduced median OS in KIF20A-high NSCLC patients (27.5 months, 95% CI: 21.4–33.6) versus low-expression group(44.4 months, 95% CI: 36.8–51.9).